Lipella Pharmaceuticals Inc is a biotechnology company based in Pittsburgh, PA, specializing in supportive care for cancer survivors with hemorrhagic cystitis, also known as radiation cystitis, and improved surveillance and imaging for patients with a history of transitional cell carcinoma. They also focus on the treatment of oral lichen planus using their proprietary drug delivery system to the oral mucosa.
With a sterile manufacturing facility in Pittsburgh, PA, Lipella Pharmaceuticals Inc produces clinical supplies and research products. They have recently completed a phase 2A multi-center dose-escalation clinical trial for their lead product, LP-10, and have submitted their pipeline asset, LP-310, for initial IND review by the FDA. Lipella Pharmaceuticals Inc aims to address highly-morbid indications where no adequate treatments currently exist through the development of proprietary assets.
Generated from the website
